Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GNMK

GenMark Diagnostics (GNMK) Stock Price, News & Analysis

GenMark Diagnostics logo

About GenMark Diagnostics Stock (NASDAQ:GNMK)

Advanced Chart

Key Stats

Today's Range
$24.04
$24.04
50-Day Range
$23.89
$24.04
52-Week Range
$8.42
$24.25
Volume
N/A
Average Volume
2.70 million shs
Market Capitalization
$1.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive GNMK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GenMark Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GNMK Stock News Headlines

Quest Diagnostics Incorporated (DGX)
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
Genmark Diagnos Share Chat
See More Headlines

GNMK Stock Analysis - Frequently Asked Questions

GenMark Diagnostics, Inc. (NASDAQ:GNMK) announced its quarterly earnings data on Thursday, February, 25th. The medical equipment provider reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.04. The medical equipment provider had revenue of $50.08 million for the quarter, compared to analyst estimates of $50 million. GenMark Diagnostics had a negative net margin of 16.95% and a negative trailing twelve-month return on equity of 39.36%.

Based on aggregate information from My MarketBeat watchlists, some other companies that GenMark Diagnostics investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Enphase Energy (ENPH) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
2/25/2021
Today
8/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:GNMK
CIK
1487371
Fax
N/A
Employees
618
Year Founded
2010

Profitability

EPS (Trailing Twelve Months)
($0.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$47.35 million
Net Margins
-16.95%
Pretax Margin
N/A
Return on Equity
-39.36%
Return on Assets
-13.02%

Debt

Debt-to-Equity Ratio
0.75
Current Ratio
4.33
Quick Ratio
3.84

Sales & Book Value

Annual Sales
$88.02 million
Price / Sales
19.96
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.21 per share
Price / Book
114.48

Miscellaneous

Outstanding Shares
73,086,000
Free Float
N/A
Market Cap
$1.76 billion
Optionable
Optionable
Beta
3.02

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:GNMK) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners